New research reveals marine bacteria contain diverse biosynthetic gene clusters capable of producing valuable bioactive compounds. The discovery of rare and cryptic clusters opens new avenues for pharmaceutical development.
Computational biology meets cancer research as AlphaFold-predicted peptide scaffolds enable more accurate drug testing in endometrial cancer organoids. This integration of AI and experimental biology could accelerate personalized medicine approaches for treatment-resistant cancers.
A rationally designed 23-residue peptide mimicking human ACE2 demonstrates significant antiviral activity against multiple SARS-CoV-2 strains. The optimized helical peptide shows promise as a therapeutic platform against coronaviruses using ACE2 for cellular entry.
Scientists have developed an optimized peptide decoy that effectively mimics the SARS-CoV-2 Spike protein’s natural binding partner, ACE2, according to recent research published in Scientific Reports. The 23-residue helical peptide demonstrated a Therapeutic Index exceeding approximately 20 in authentic viral cell challenge assays, including against both wild-type and Omicron variants, sources indicate.
Scientists have engineered advanced nanogel systems that effectively encapsulate and protect negatively charged therapeutic molecules. The breakthrough technology demonstrates significant potential for improving delivery of challenging biopharmaceuticals like nucleic acid-based drugs while maintaining excellent biocompatibility.
Researchers have developed a groundbreaking peptide-based nanogel system that shows remarkable potential for delivering negatively charged therapeutic molecules, according to recent scientific reports. The technology addresses a significant challenge in pharmaceutical science: effectively encapsulating and protecting anionic bioactive compounds that have traditionally been difficult to administer.
